Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Nektar is a biopharmaceutical company focused on two technology platforms: PEGylation and pulmonary drug delivery. The company operates in a single business segment. As of the reporting date, the company was in the process of divesting its pulmonary technology assets to Novartis Pharmaceuticals.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Total Revenue | $21,439 | $61,832 | - |
| Net Loss | $(37,038) | $(111,118) | - |
| Loss Per Share (Basic/Diluted) | $(0.40) | $(1.20) | - |
| Cash & Cash Equivalents | - | - | $63,713 |
| Short-term Investments | - | - | $280,803 |
| Total Assets | - | - | $568,352 |
| Convertible Subordinated Notes | - | - | $315,000 |
| Net Cash Used in Operating Activities | $(18,600) (Est.) | $(115,065) | - |
Note: Three-month operating cash flow is estimated based on MD&A text stating $18.6 million usage.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 62% for the three months and 70% for the nine months ended September 30, 2008, compared to the same periods in 2007. This was primarily due to the termination of the partnership with Pfizer regarding Exubera and Next-Generation Inhaled Insulin (NGI), which accounted for 61% and 68% of revenue in the prior year periods, respectively.
- Net Loss Increase: Net loss widened significantly to $37.0 million for the quarter and $111.1 million for the nine-month period, compared to $18.6 million and $71.8 million in 2007.
- Asset Restructuring: The company classified $42.975 million in assets as "Assets held for sale" in connection with the sale of its pulmonary technology platform to Novartis. This includes capital equipment and investments in Pearl Therapeutics Inc.
- Workforce Reduction: The company executed workforce reduction plans in 2007 and 2008, reducing staff by approximately 25% and 20% respectively. Costs associated with these plans were $5.0 million for the nine months ended September 30, 2008.
Guidance, Outlook, and Risks
- Novartis Transaction: On October 20, 2008, Nektar entered an Asset Purchase Agreement to sell its pulmonary technology assets to Novartis for $115.0 million in cash. Closing is expected on or about December 31, 2008. Upon closing, Nektar will retain rights to NKTR-061 (inhaled amikacin), NKTR-063 (inhaled vancomycin), and its PEGylation platform.
- Debt Repurchase: Subsequent to the reporting period (as of November 7, 2008), the company repurchased approximately $100.0 million face value of its 3.25% convertible subordinated notes for $47.8 million, reducing outstanding debt to $215.0 million.
- Liquidity: Management believes cash and short-term investments ($344.5 million total) are sufficient to meet anticipated needs for at least the next twelve months, despite negative operating cash flow.
- Risks: Key risks include the uncertainty of the Novartis transaction closing, the failure of proprietary product candidates (NKTR-102, NKTR-118) in clinical trials, and the inability to generate sufficient cash flow to meet debt obligations maturing in 2012.
Investor Verification Checklist
- Novartis Deal Closing: Verify the status of the $115 million asset sale to Novartis and whether all regulatory and third-party consents have been obtained.
- Debt Obligations: Confirm the remaining balance of the 3.25% convertible notes ($215 million) and the company's ability to refinance or repay this debt upon maturity in September 2012.
- Clinical Progress: Monitor Phase 2 clinical trial results for proprietary candidates NKTR-102 (PEG-irinotecan) and NKTR-118 (oral PEG-naloxol), which are critical for future revenue generation.
- Exubera Liability: Review any potential lingering liabilities or indemnification obligations related to the terminated Pfizer partnership and the Exubera lung cancer safety data.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate given the cessation of major revenue streams from Pfizer and the reliance on investment income and milestone payments.